Table 7.
Days | Control * | F5 * | Commercial Product * |
---|---|---|---|
3rd day | 05.106% ± 0.110 | 25.633% ± 0.549 | 15.146% ± 0.254 |
5th day | 20.050% ± 0.055 | 40.483% ± 0.422 | 30.236% ± 0.409 |
7th day | 25.433% ± 0.388 | 55.536% ± 0.474 | 46.590% ± 0.510 |
9th day | 40.233% ± 0.245 | 60.583% ± 0.514 | 60.326% ± 0.473 |
11th day | 55.313% ± 0.419 | 80.443% ± 0.403 | 78.026% ± 0.380 |
13th day | 60.420% ± 0.435 | 90.430% ± 0.603 | 89.253% ± 1.090 |
15th day | 70.846% ± 0.830 | 100.000% ± 0.015 | 98.170% ± 0.749 |
* Control: formulation without Eu; F5 group: optimized formulation; commercial product: Quench Cream®, containing silver sulphadiazine. The data is presented as mean ± SD and analyzed using one way ANOVA. p < 0.02 and p < 0.04 refers to statistical significance of both groups from the control.